Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course

Abstract: Pregabalin (PGB) is an anticonvulsivant drug that binds to α2-δ subunit of the N-type voltagedependent Ca-channel (VDCC). VDCC-containing subunits appear to be involved in presynaptic regulation of neurotransmitter release. It has been shown that PGB is capable of inhibiting glutamate, noradrenaline, acetylcholine and substance P release at several different central nervous system locations including the neocortex, the amygdala, the hippocampus, the striatum, the spinal cord, the cerebellum and the habenula. PGB is approved by the United States Food and Drug Administration for the treatment of painful diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia, and as adjunctive therapy in adults with partial-onset seizure disorder. In Europe, pregabalin is also approved for neuropathic pain and generalized anxiety disorder. PGB effects on sleep quality and Health-related Quality of Life (HRQoL) have been studied in many clinical trials. For example, a recent meta-analysis has shown that PGB 150-600 mg/day significantly improved pain-related sleep interference in patients with neuropathic pain. HRQoL was also improved by PGB. It has been suggested that improvements on sleep or HRQoL may be correlated to PGB analgesic effects, but the magnitude of such correlation remains unknown. Therefore, we conducted the present study aiming at further exploring the correlation between changes in pain intensity, sleep quality and HRQoL after a PGB 8-week treatment course.

Saved in:
Bibliographic Details
Main Authors: Pérez Lloret, Santiago, Meza Rojas, Gloria, Menoni, María Celia, Ruiz, Gabriela, Velásquez, Carolina, Rodriguez, Hernán, Rey, Verónica, Cardinali, Daniel Pedro
Format: Artículo biblioteca
Language:eng
eng
Published: Lippincott, Williams & Wilkins 2012
Subjects:PREGABALINA, SUEÑO, DOLOR, CALIDAD DE VIDA, SALUD,
Online Access:https://repositorio.uca.edu.ar/handle/123456789/1624
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:ucacris:123456789-1624
record_format koha
spelling oai:ucacris:123456789-16242020-08-06T19:41:42Z Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course Pérez Lloret, Santiago Meza Rojas, Gloria Menoni, María Celia Ruiz, Gabriela Velásquez, Carolina Rodriguez, Hernán Rey, Verónica Cardinali, Daniel Pedro PREGABALINA SUEÑO DOLOR CALIDAD DE VIDA SALUD Abstract: Pregabalin (PGB) is an anticonvulsivant drug that binds to α2-δ subunit of the N-type voltagedependent Ca-channel (VDCC). VDCC-containing subunits appear to be involved in presynaptic regulation of neurotransmitter release. It has been shown that PGB is capable of inhibiting glutamate, noradrenaline, acetylcholine and substance P release at several different central nervous system locations including the neocortex, the amygdala, the hippocampus, the striatum, the spinal cord, the cerebellum and the habenula. PGB is approved by the United States Food and Drug Administration for the treatment of painful diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia, and as adjunctive therapy in adults with partial-onset seizure disorder. In Europe, pregabalin is also approved for neuropathic pain and generalized anxiety disorder. PGB effects on sleep quality and Health-related Quality of Life (HRQoL) have been studied in many clinical trials. For example, a recent meta-analysis has shown that PGB 150-600 mg/day significantly improved pain-related sleep interference in patients with neuropathic pain. HRQoL was also improved by PGB. It has been suggested that improvements on sleep or HRQoL may be correlated to PGB analgesic effects, but the magnitude of such correlation remains unknown. Therefore, we conducted the present study aiming at further exploring the correlation between changes in pain intensity, sleep quality and HRQoL after a PGB 8-week treatment course. 2019-05-02T14:01:10Z 2019-05-02T14:01:10Z 2012 Artículo Pérez Lloret, S., et al. Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course [en línea]. Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1). Disponible en: https://repositorio.uca.edu.ar/handle/123456789/1624 0362-5664 1537-162X (online) https://repositorio.uca.edu.ar/handle/123456789/1624 10.1097/WNF.0b013e31823df2dc eng eng Acceso Abierto https://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf Lippincott, Williams & Wilkins Preprint del documento publicado en Clinical Neuropharmacology 2012, 35 (1)
institution UCA
collection DSpace
country Argentina
countrycode AR
component Bibliográfico
access En linea
databasecode dig-uca
tag biblioteca
region America del Sur
libraryname Sistema de bibliotecas de la UCA
language eng
eng
topic PREGABALINA
SUEÑO
DOLOR
CALIDAD DE VIDA
SALUD
PREGABALINA
SUEÑO
DOLOR
CALIDAD DE VIDA
SALUD
spellingShingle PREGABALINA
SUEÑO
DOLOR
CALIDAD DE VIDA
SALUD
PREGABALINA
SUEÑO
DOLOR
CALIDAD DE VIDA
SALUD
Pérez Lloret, Santiago
Meza Rojas, Gloria
Menoni, María Celia
Ruiz, Gabriela
Velásquez, Carolina
Rodriguez, Hernán
Rey, Verónica
Cardinali, Daniel Pedro
Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
description Abstract: Pregabalin (PGB) is an anticonvulsivant drug that binds to α2-δ subunit of the N-type voltagedependent Ca-channel (VDCC). VDCC-containing subunits appear to be involved in presynaptic regulation of neurotransmitter release. It has been shown that PGB is capable of inhibiting glutamate, noradrenaline, acetylcholine and substance P release at several different central nervous system locations including the neocortex, the amygdala, the hippocampus, the striatum, the spinal cord, the cerebellum and the habenula. PGB is approved by the United States Food and Drug Administration for the treatment of painful diabetic peripheral neuropathy, fibromyalgia, and postherpetic neuralgia, and as adjunctive therapy in adults with partial-onset seizure disorder. In Europe, pregabalin is also approved for neuropathic pain and generalized anxiety disorder. PGB effects on sleep quality and Health-related Quality of Life (HRQoL) have been studied in many clinical trials. For example, a recent meta-analysis has shown that PGB 150-600 mg/day significantly improved pain-related sleep interference in patients with neuropathic pain. HRQoL was also improved by PGB. It has been suggested that improvements on sleep or HRQoL may be correlated to PGB analgesic effects, but the magnitude of such correlation remains unknown. Therefore, we conducted the present study aiming at further exploring the correlation between changes in pain intensity, sleep quality and HRQoL after a PGB 8-week treatment course.
format Artículo
topic_facet PREGABALINA
SUEÑO
DOLOR
CALIDAD DE VIDA
SALUD
author Pérez Lloret, Santiago
Meza Rojas, Gloria
Menoni, María Celia
Ruiz, Gabriela
Velásquez, Carolina
Rodriguez, Hernán
Rey, Verónica
Cardinali, Daniel Pedro
author_facet Pérez Lloret, Santiago
Meza Rojas, Gloria
Menoni, María Celia
Ruiz, Gabriela
Velásquez, Carolina
Rodriguez, Hernán
Rey, Verónica
Cardinali, Daniel Pedro
author_sort Pérez Lloret, Santiago
title Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
title_short Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
title_full Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
title_fullStr Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
title_full_unstemmed Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
title_sort pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an eight-week treatment course
publisher Lippincott, Williams & Wilkins
publishDate 2012
url https://repositorio.uca.edu.ar/handle/123456789/1624
work_keys_str_mv AT perezlloretsantiago pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse
AT mezarojasgloria pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse
AT menonimariacelia pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse
AT ruizgabriela pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse
AT velasquezcarolina pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse
AT rodriguezhernan pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse
AT reyveronica pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse
AT cardinalidanielpedro pregabalinbeneficialeffectsonsleepqualityorhealthrelatedqualityoflifearepoorlycorrelatedwithreductiononpainintensityafteraneightweektreatmentcourse
_version_ 1756275062540861440